渗透剂(生化)
药物开发
医学
药理学
替莫唑胺
偶然性
药品
癌症研究
胶质母细胞瘤
生物
生物技术
认识论
哲学
作者
Filipa Lynce,Nancy U. Lin
标识
DOI:10.1158/1078-0432.ccr-23-3571
摘要
Abstract Primary and secondary brain tumors cause significant mortality and constitute an important unmet need. The development of AZD9574, a brain-penetrant, PARP1 selective inhibitor, with favorable pharmacologic properties and intriguing preclinical activity, has led to an ongoing clinical trial evaluating it alone and in combination with temozolomide or antibody drug conjugates.
科研通智能强力驱动
Strongly Powered by AbleSci AI